Zobrazeno 1 - 10
of 147
pro vyhledávání: '"Alan B. Sandler"'
Supplementary Figure S1 from Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff49ba931b0ea409807c915349e1eb1
https://doi.org/10.1158/1078-0432.22441260.v1
https://doi.org/10.1158/1078-0432.22441260.v1
Background: E4599 was a phase II/phase III trial, in which 878 patients with advanced non–small cell lung cancer were randomized to carboplatin + paclitaxel (PC arm) or PC + bevacizumab (BPC arm). Survival and progression-free survival were superio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::537ba35154ca99d88eb38097c7ca8766
https://doi.org/10.1158/1078-0432.c.6518373.v1
https://doi.org/10.1158/1078-0432.c.6518373.v1
Autor:
Iona Cheng, Shih-Wen Lin, Manali I. Patel, Juan Yang, Scarlett Lin Gomez, Heather A. Wakelee, Christina A. Clarke, Margaret Elizabeth McCusker, Alan B. Sandler
Publikováno v:
Journal of Global Oncology
Purpose Despite being the leading cause of cancer death, no prior studies have characterized survival patterns among Chinese Americans diagnosed with lung cancer. This study was conducted to identify factors associated with survival after lung cancer
Autor:
Alan B. Sandler, Ariel Lopez-Chavez
Publikováno v:
Current Problems in Cancer. 36:131-155
Autor:
Heinrich Roder, Anne S. Tsao, Maxim Tsypin, Joanna Roder, Thao P. Dang, Hai T. Tran, David P. Carbone, J. Stuart Salmon, Dean Billheimer, Heidi Chen, Roy S. Herbst, Alan B. Sandler
Publikováno v:
Lung Cancer. 69:337-340
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat®) in a blinded manner to pre-treatment sera obtained from recurrent advanced NSCLC patients before treatment with
Publikováno v:
Journal of Clinical Oncology. 28:949-954
Purpose Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) with demonstrated efficacy in combination with carboplatin and paclitaxel (PCB) for the treatment of advanced non–small-cell lung cancer (NSCLC). Ad
Autor:
Heidi Chen, Ju Whei Lee, Joan H. Schiller, Alan B. Sandler, Shuo Chen, Julie R. Brahmer, Hai T. Tran, Stuart Salmon, Anne Tsao, Dean Billheimer, Roy S. Herbst, Pierre P. Massion, Thao P. Dang, Yu Shyr, David P. Carbone
Publikováno v:
Journal of Thoracic Oncology. 4:689-696
PurposeAlthough many lung cancers express the epidermal growth factor receptor and the vascular endothelial growth factor, only a small fraction of patients will respond to inhibitors of these pathways. Matrix-assisted laser desorption/ionization tim
Autor:
Anshu K. Jain, Alan B. Sandler, Afshin Dowlati, Jean Wu, Randall S. Hughes, Hak Choy, Larry Schlabach, Nancy J. Muldowney, Lee S. Schwartzberg, Tracy Dobbs
Publikováno v:
Journal of Thoracic Oncology. 4:722-727
Introduction The current standard of care for good performance status patients with locally advanced non-small cell lung carcinoma is concurrent chemoradiation, although a clearly superior regimen has not been identified. Docetaxel has been shown to
Autor:
David H. Johnson, Meghna Samant, J. Brahmer, Alan B. Sandler, Lisa I. Wang, Robert Gray, Joan H. Schiller, Isaiah W. Dimery
Publikováno v:
Journal of Clinical Oncology. 27:1405-1412
Purpose Severe (grade ≥ 3) pulmonary hemorrhage (PH) in advanced non–small-cell lung cancer was observed in two prospective, randomized, phase II (N = 99) and phase III (N = 878) trials of bevacizumab plus carboplatin and paclitaxel. Retrospectiv
Autor:
Alan B. Sandler, Leora Horn
Publikováno v:
Clinical Lung Cancer. 10:S7-S16
Lung cancer is the leading cause of cancer-related mortality in the United States. Patients treated with adjuvant chemotherapy have a 5-year survival rate of 25% to 70% depending on stage, whereas those with advanced disease have a median survival of